Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the treatment of type 2 diabetes mellitus and, in specific formulations, for weight management
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
Key genetic variantssuch as GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313influence how many GLP-1 receptors your cells express and how sensitively they respond to the drug
TB-500 itself has anti-inflammatory and tissue repair properties that are relevant to psoriasis
Similarly, an earlier review including only five RCTs provided solely qualitative synthesis of AID in type 2 diabetes [14]